Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634581 | 0.80 | ALDH1A1 (0.65) | CYP19A1CACNA1GCACNA1IALDH1A1NPC1 | |
| SCHEMBL18096199 | 0.77 | CACNA1G (0.49) | CACNA1GCACNA1IALDH1A1NPC1RAB9A | |
| SCHEMBL18577540 | 0.76 | CYP19A1 (0.48) | CYP19A1CACNA1GCACNA1IALDH1A1NPC1 | |
| SCHEMBL22149669 | 0.76 | CYP19A1 (0.48) | CYP19A1CACNA1GCACNA1IALDH1A1NPC1 | |
| SCHEMBL10247346 | 0.76 | GFER (0.60) | CYP19A1CACNA1GCACNA1IALDH1A1NPC1 | |
| SCHEMBL8011610 | 0.76 | CACNA1G (0.51) | CYP19A1CACNA1GCACNA1IALDH1A1NPC1 | |
| SCHEMBL7862499 | 0.76 | NPC1 (0.49) | CYP19A1CACNA1GCACNA1IALDH1A1NPC1 | |
| SCHEMBL18593139 | 0.76 | ALDH1A1 (0.51) | CYP19A1CACNA1GCACNA1IALDH1A1NPC1 | |
| SCHEMBL5869934 | 0.74 | HDAC1 (0.55) | CYP19A1CACNA1GCACNA1IALDH1A1NPC1 | |
| SCHEMBL7494123 | 0.74 | RAB9A (0.68) | CYP19A1CACNA1GCACNA1IALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327809-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327809-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3344624-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3344624-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230074228-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-11434240-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210047319-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-18 | — | — | US | disclosed |
| US-20210047319-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-18 | — | — | US | disclosed |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20180354949-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-13 | — | — | US | disclosed |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3344624-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| WO-2017040757-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040757-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885CACNA1G 4454/4885CACNA1I 4089/4885 |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK1, JAK2 | CYP19A1 1705/4885CACNA1G 4290/4885CACNA1I 3256/4885 |
| US-11434240-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK1, JAK2 | CYP19A1 1705/4885CACNA1G 4290/4885CACNA1I 3256/4885 |
| US-20210047319-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885CACNA1G 4454/4885CACNA1I 4089/4885 |
| US-20180354949-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885CACNA1G 4454/4885CACNA1I 4089/4885 |
| US-20230074228-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885CACNA1G 4454/4885CACNA1I 4089/4885 |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK1, JAK2 | CYP19A1 1705/4885CACNA1G 4290/4885CACNA1I 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.